SNY Related Analyst Ratings
-
Deutsche Bank Initiates Coverage on Sanofi-Aventis (SNY) with a Buy
-
Barclays Starts NVO, SNY at Overweight, GSK, AZN at Equalweight, NVS at Underweight
-
UBS Upgrades Sanofi-Aventis (SNY) to Neutral
-
Barron's Article Makes Comments on Activision Blizzard (ATVI); Shares Could Rise 29% in a Year
-
Leerink Swann Analyst Says Bristol-Myers Squibb (BMY) Shares Fully Valued vs. Peers
-
J.P. Morgan Upgrades Sanofi-aventis (SNY) to Overweight
-
Nomura Downgrades Sanofi-aventis (SNY) to Neutral
-
SocGen Downgrades Sanofi-aventis (SNY) to Hold
-
Morgan Stanley Upgrades Sanofi-aventis (SNY) to Overweight
-
Leerink Swann Downgrades MannKind (MNKD) to Underperform; Not Enough Visibility on Afresa's Future
-
J.P. Morgan Downgrades Sanofi-Aventis (SNY) to Neutral
-
Analysts Downgrade Sanofi Aventis Amid Long-Acting Insulin Concerns; Amylin Benefiting (SNY, AMLN, NVO)
-
Cowen & Co Initiates Coverage on Sanofi-Aventis (SNY) with a Neutral
-
J.P. Morgan Upgrades Sanofi-Aventis (SNY) to Overweight
-
Jefferies & Co Upgrades Sanofi-Aventis (SNY) to Hold
-
Credit Suisse Initiates Coverage on Sanofi-Aventis (SNY) with an Outperform
-
J.P. Morgan Upgrades Sanofi-Aventis (SNY) to Neutral
-
Jefferies & Co Initiates Coverage on Sanofi-aventis (SNY) with an Underperform
-
Deutsche Bank Maintains a 'Hold' Rating on Sanofi-Aventis (SNY)
-
Morgan Stanley Upgrades Sanofi-Aventis (SNY) to Overweight
-
Merrill Lynch Upgrades sanofi-aventis (SNY) to Buy
-
Credit Suisse Downgrades Sanofi-Aventis (SNY) to Underperform
-
Morgan Stanley Downgrades Sanofi-Aventis (SNY) to Equalweight
-
Deutsche Bank Downgrades Sanofi-Aventis (SNY) to Hold
-
HSBC Downgrades Sanofi-Aventis (SNY) to Neutral
-
Goldman Sachs downgrades Sanofi-Aventis (SNY) to Neutral
-
JP Morgan Downgrades Sanofi-Aventis (SNY) to Neutral
-
Jim Cramer Makes Positive Comments on NSTK, ACAD and SNY
-
Goldman Sachs Upgrades Sanofi-Aventis (SNY) to Buy
-
Lehman Brothers downgrades Sanofi-Aventis (SNY) to Equal-Weight
-
Merrill Lynch upgrades Sanofi-Aventis (SNY) to Buy
-
HSBC upgrades Sanofi-Aventis (SNY) to Overweight
-
Banc of America Starts Sanofi-Aventis (SNY) at Buy
-
Bear Stearns downgrades Sanofi-Aventis (SNY) to Underperform
-
Stifel Nicolaus Said NutriSystem (NTRI) Growth Safe For Now Following Sanofi-Aventis Rimonabant News
-
Stifel Nicolaus Said NutriSystem (NTRI) Investors Should Listen to Sanofi's Earningss Call
-
Sanofi-Aventis (SNY) implied volatility Expensive prior to lowered Forecast
-
Citigroup upgrades Sanofi-Aventis (SNY) to Hold
-
House and Senate Negotiators agreed on $2.3B Avian Flu Funding - Analyst
-
Lehman Bros. Upgrades Sanofi-Aventis (SNY) to Overweight
-
Lehman Brothers upgrades Sanofi-Aventis (SNY) to Overweight
-
Citigroup downgrades SNY to Sell
-
Hearing Lehman Brothers Upgraded SNY to Equal-Weight
-
UBS Downgraded SNY
-
UBS Securities Downgrades SNY
-
Bear Stearns downgrades SNY to Peer Perform
-
JP Morgan upgrades SNY to Overweight
-
JMP Securities Comments on Potential Beneficiaries of Avian Flu Pandemic
-
Piper Jaffray Expects Exubera to Be Approved in Nov
-
Prudential Downgrades SNY
Back to SNY Stock Lookup
